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Abstract: Mesenchymal Stem Cells (MSCs), have been defined and characterized by: 1) their ability to adhere to plastic 
culture flasks; 2) the positive expression of CD105, CD73, CD90 membrane antigens, and the lack of expression of others 
(e.g CD45 and CD34) and 3) the ability of differentiation under adequate conditions along the osteogenic, chondrogenic 
and adipogenic lineages. In recent years, cells with these characteristics have been isolated from the Wharton’s jelly of the 
Umbilical Cord (UC). Similarly to bone marrow MSCs, they have shown multilineage differentiation potential and to be 
able to provide trophic support to neighboring cells. According to the literature, there are two main populations of cells 
with a mesenchymal character within the human UC: Wharton's jelly Mesenchymal Stem Cells (WJ-MSCs) and Human 
Umbilical Cord Perivascular Cells (HUCPVCs). In the present work our aim is to make a comprehensive review on MSC 
populations of the UC and how these cell populations may be used for future applications in CNS regenerative medicine. 
Following a brief insight on the general characteristics of MSC like cells, we will discuss the possible sources of stem 
cells within the WJ and the cord itself (apart UC blood), as well as their phenotypic character. As it has already been 
shown that these cells hold a strong trophic support to neighbouring cell populations, we will then focus on their secre-
tome, namely which molecules have already been identified within it and their role in phenomena such as immunomodu-
lation. The possible applications of these cell populations to CNS regenerative medicine will be addressed by critically 
reviewing the work that has been performed so far in this field. Finally, a brief insight will be made on what in the 
authors’ opinion are the major challenges in the field for the future application of these cell populations in CNS 
regenerative medicine. 
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1. INTRODUCTION 
 The identification of Mesenchymal Stem Cells (MSCs) 
followed the pioneering work of Alexander Friedenstein and 
colleagues, who discovered that within the bone marrow 
compartment existed a population of non-hematopoietic cells 
with osteogenic potential [1]. Furthermore, he developed a 
method of isolating these cells based on their adherence to 
plastic surfaces, reporting that they developed into fibro-
blast-shaped cell cultures with high replicative and clono-
genic potential [2]. Since then, human MSCs (hMSCs), or 
cells with a MSC-like phenotype have been identified and 
isolated from several adult and fetal tissues, namely bone 
marrow [3-5], adipose tissue [6, 7], circulating blood [4, 8], 
dental pulp [9-11], placenta [12, 13], amniotic fluid [14, 15], 
umbilical cord blood [16], subendothelial layer of umbilical 
cord vein [17], umbilical cord Wharton’s jelly (WJ) [18, 19], 
umbilical cord perivascular  
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layer [20], pancreas [21], liver [4, 5], lung and spleen [5]. 
They are commonly characterized by: 1) the ability to adhere 
to plastic culture flasks; 2) the expression in 95% of the 
MSC population of CD105, CD73 and CD90 membrane 
antigens, and the lack of expression of CD45, CD34, CD14, 
CD11b, CD79 or CD19 and HLA class II; and 3) the ability 
of differentiation under adequate conditions into at least  
osteoblasts, chondrocytes and adipocytes [22, 23].  
 Despite these common traits, these cells do present subtle 
changes in their expression profile. Such changes can be the 
result of tissue-specific environments; however, as already 
pointed by others, one should also take into account that dif-
ferences in culture protocols may influence the identity of 
MSC populations [24, 25]. In addition to CD105, CD73 and 
CD90, other membrane antigens, namely CD29, CD44, 
CD51, CD71, CD106, CD166 and Stro-1, have been associ-
ated with a MSC-like identity [24, 26]. Besides the deriva-
tion towards the osteogenic, chondrogenic and adipogenic 
lineages [24, 26, 27], the derivation of other mesenchymal 
cell types, namely myocytes and tenocytes, from MSCs, has 
also been documented [26, 27]. Interestingly, several reports 
argued that MSCs can be derived into cell types without a 
mesoderm/mesenchymal origin, namely neurons or epithelial 
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cells, thus disrupting the contingencies of embrionary devel-
opment [26]. However, while the derivation of epithelial 
cells seems likely to occur, the data concerning the differen-
tiation into neural cells is rather questionable and mined with 
both variations in differentiation protocols and lack of con-
clusive functional studies [26]. As in the case of the pheno-
typic profile of MSCs, the differentiation potential of each 
MSC population may be different. Inconsistencies in culture 
protocols can help explain such variation, but interestingly 
even when cultured under the same conditions, some MSC 
populations were shown to have limited capacity to derivate 
into certain cell types [28-31].  
 Due to the widespread availability of MSCs and their 
remarkable ability to differentiate into several mesenchymal 
lines, they were soon thought to be suitable candidates for 
the therapeutical repair of lesioned tissues. Hence, several 
strategies using MSCs, differentiated MSCs, genetically en-
gineered MSCs, or MSCs combined with biomaterials were 
already developed for the treatment of several lesions, some 
of them with quite promising results [24, 27, 32]. As an ex-
ample, bone marrow MSCs were shown to have beneficial 
effects when transplanted into patients suffering from os-
teogenesis imperfecta [33, 34]. However, in recent years 
several studies have reported that MSCs’ therapeutical appli-
cation may be extended beyond tissue transplantation proto-
cols. Indeed, MSCs were found to produce and secrete mul-
tiple paracrine factors with therapeutical relevance for their 
anti-apoptotic, angiogenic, anti-scaring, immunomodulatory 
and chemoattractive activities [25, 35]. In this context, un-
derstanding the role of the various mechanisms involved in 
the environment of these stem cell “niches” is of the utmost 
importance to understand not only the concept of stem cell 
biology but also for the establishment of in vitro culture pro-
tocols meant for biomedical use. Thus, in addition to the 
clarification of the phenotypic identity and culture parame-
ters of MSC populations, nowadays is becoming extremely 
relevant the detailed characterization of MSCs secretome, as 
the factors secreted by these cells may be the main effectors 
of their therapeutic action. 
 Of particular interest is the possible application of the 
outcomes of MSCs related research for the development of 
new therapies for several neurodegenerative diseases. When 
applied to the central nervous system (CNS), MSCs are con-
sidered as cytotrophic mediators because their secretome is 
rich in neurotrophic factors, which promote neurogenesis 
and increase neuronal survival. In fact, due to its increasing 
importance, this topic has been addressed in a number of 
studies, namely dealing with stem cells isolated from the 
bone marrow (BMSCs) [36-39] and adipose tissue (ASCs) 
[40-44]. However, in recent studies stem cells isolated from 
the WJ have also disclosed similar trophic properties. There-
fore, the aim of the present review is to summarize published 
data related to the characterization of the phenotypic identity, 
immunologic properties and secretome of stem cells with a 
mesenchymal phenotype isolated from the UCs’ WJ. Addi-
tionally, we also intend to review experimental data with the 
purpose of discussing the possible applications of these cells 
in future therapies dealing with the treatment of central nerv-
ous system-related injuries/diseases, namely through mecha-
nisms mediated by their secretome.   
2. UMBILICAL CORD MESENCHYMAL STEM 
CELLS 
2.1. Phenotypic Identity  
 The interest in the umbilical cord as a source of MSCs 
developed after early studies reporting the isolation of MSC-
like cells from the umbilical cord blood [16]. However, the 
isolation yields for MSCs reported so far have been too low 
to consider umbilical cord blood MSCs as a clinically viable 
cell population for therapeutical use [45]. In recent years, 
other tissues within the umbilical cord were found to be rich 
in MSC-like cells. The discovery of such MSC niches came 
to support early studies showing the presence of fibroblast-
shaped, plastic-adherent cells in the UC’s WJ [46]. Later on, 
these cells were shown to be capable of chondrogenic deriva-
tion under proper differentiation conditions [47].  
 The definite classification of these cells as MSCs came 
from the work of Wang et al., who in 2004 described their 
phenotype and their potential to differentiate along several 
mesenchymal lineages [18]. Briefly, these cells presented a 
fibroblast shape in culture, were positive for CD29, CD44, 
CD51, CD105, SH2 and SH3, and negative for 
hematopoietic cell markers, namely CD34 and CD45 [18]. 
Moreover, it was shown to be possible to derive WJ-MSCs 
into functionally viable adipocytes and osteocytes [18]. 
Chondrogenic differentiation was also attained, but the ex-
pression of chondrocyte-associated markers in an undifferen-
tiated state led the authors to hypothesize that these cells 
could in fact be prone to derivation along the chondrogenic 
lineage [18]. Further studies confirmed the phenotypic iden-
tity and differentiation potential of WJ-MSCs [19, 48-53] 
and provided additional data, particularly in respect to the 
growth pattern of human WJ-MSCs [48]. These cells pre-
sented a 6-7 day lag phase and a log phase of 6-8 days. 
Population doubling time (PDT) ranged from 85±7,2h in P0 
state to 11±1,2h in P7. Morphological analysis however, 
showed that the isolated population could be in fact consti-
tuted by two sub-populations. The authors described cells 
presenting filapodia with a widened appearance and rich in 
pancytokeratin, designted type 1 cells, and fusiform-shaped 
cells with long cytoplasmic extensions but no pancytokeratin 
expression, which were designated type 2 cells. Moreover, 
and although both cell types presented chondrogenic, adipo-
genic and osteogenic differentiation potential, in situ labeling 
showed that type 1 cells were confined to the perivascular 
areas of the umbilical cord, whereas type 2 cells had a wide-
spread distribution, except for perivascular areas. Based on 
these results it seems likely that type 2 cells reported by 
Karahuseyinoglu et al. [48], are in fact WJ-MSCs. In addi-
tion, type 1 cells showed tendency to diminish in number 
with subsequent passages and were unable to acquire a neu-
ronal morphology, unlike type 2 cells that when exposed to a 
neurodifferentiation media did show such ability. Interest-
ingly, both porcine and human WJ-MSCs cultured under 
neurogenic conditions were shown to acquire a neuronal-like 
phenotype [48, 54-56]. According to these reports, these 
cells acquired a neuronal shape with the formation of axon-
like processes, and even expressed neuronal or neural stem 
cell markers including TuJ1, NSE, NFE, MAP-2, NF, NeuN, 
TH, and glial ones (GFAP, CD11b), both in vivo and in vitro 
[48, 49, 54-56]. However, expression of some of these mark-
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ers is also found in basal conditions, without exposure to 
differentiation protocols [54, 55]. Additionally, functional 
evidences regarding the electrophysiological activity of 
MSC-derived neurons were not clearly evident [48, 49, 54-
56], and therefore further studies need to be done on this 
topic. 
 In the case of type 1 cells, prior to the work of Kara-
huseyinoglu et al., a perivascular MSC-like population had 
been already described by Sarugaser et al., [20]. These cells 
were shown to be efficiently isolated from the perivascular 
region of the umbilical cord, and to have a colony forming 
unit (CFU) frequency of 1:333 [20]. Furthermore, growth 
profile was strikingly different from the one reported by 
Karahuseyinoglu et al. for a mixed umbilical cord MSC 
population mainly constituted by WJ-MSCs [48]. Human 
umbilical cord perivascular cells (HUCPVC) presented a 24h 
lag phase, a log phase of at least 96h, and PDT ranged from 
59,4±42,4h in P0 to nearly 20h in P6 [20]. Cells were positive 
for CD44, CD73, CD90 and CD105, and negative for CD34, 
CD45, CD106, CD123, CD235a, SSEA-4, HLA-DR, -DP, -
DQ, HLA-G, Oct4, and also for HLA-ABC after freez-
ing/thawing [20]. HUCPVCs were found to be highly prone 
for osteogenic differentiation, even under standard culture 
conditions, and unable to acquire a neuronal-like phenotype 
[20]. Subsequent reports showed that HUCPVC have a high 
expression of CD146 and that the presence of this marker is 
limited to the perivascular area of the umbilical cord and 
inexistent in WJ [31]. Furthermore, the derivation of chon-
drocytes and osteocytes from CD146
+
 HUCPVCs was also 
accomplished [31]. Finally Sarugaser and colleagues [57] 
revealed that HUCPVCs, contributed to rapid connective 
tissue healing in vivo by producing bone, cartilage and fi-
brous stroma. Additionally, they also exhibited a high clono-
genic frequency, allowing the isolation of definitive SCD 
parent and daughter clones from mixed gender suspensions 
as determined by Y-chromosome fluorescent in situ hybridi-
zation [57].  
 Taken together, these studies suggest that WJ-MSCs and 
HUCPVCs are in fact two different populations of MSCs 
isolated from the umbilical cord. Although they share some 
phenotypic traits and have similar mesenchymal tri-
differentiation potential, WJ-MSCs present lower growth 
rates, lack the expression of pancytokeratin and CD146, 
seem to be prone for chondrogenic differentiation and are 
able to acquire a neuronal-like phenotype; whereas 
HUCPVCs are a fast-growing MSC population, present in 
the perivascular area of the umbilical cord, with high expres-
sion levels of pancytokeratin and CD146, having tendency to 
derive along the osteogenic lineage and an inability to ac-
quire neuronal-like shape. 
 Interestingly, other authors proposed the existence of yet 
another MSC population in the umbilical cord, specifically 
within the endothelial/subendothelial area of the blood ves-
sels [17]. These cells, with a fibroblast-like morphology, are 
deprived of hematopoietic and endothelial cell markers but 
are positive for ASMA and cell adhesion markers [17]. 
Moreover, derivation into adipocytes and chondrocytes was 
efficiently accomplished [17]. Further studies complemented 
the characterization of these cells, for they showed that endo-
thelial/subendothelial MSC-like cells are CD14, CD31, 
CD34, CD45, CD51/61, CD106, CD117 and HLA-DR nega-
tive; CD13, CD29, CD44, CD49d, CD54, CD73, CD90 and 
HLA-ABC positive; and able to acquire a neuronal-like 
shape, while expressing several neuronal markers, when cul-
tured in neurodifferentiation medium [58-61]. More recently, 
Ishige and colleagues have isolated MSCs from umbilical 
cord arteries and veins, and compared these two sub-
populations [51]. No differences were found neither in re-
spect of the phenotypic profile, nor regarding the mesen-
chymal tri-differentiation ability of the cells isolated from 
those two sources [51]. However, artery-derived MSCs pre-
sented a higher growth rate with lower CFU frequency, 
whereas vein-derived MSCs presented low growth rate but 
the highest CFU frequency [51]. Despite these differences 
the reported data do not suggest that artery and vein-derived 
MSCs are in fact two separate MSCs populations. 
2.2. Immunomodulation 
 In recent years, and much like to what is already de-
scribed for BMSCs and ASCs, umbilical cord-derived MSCs 
were also found to have relevant immunomodulatory activ-
ity. WJ-MSCs, for example, were found to be able to hamper 
both Con-A and PHA-induced proliferation of in vitro sple-
nocyte and peripheral mononuclear blood cells (PMBC) cul-
tures [50, 52, 53]. This effect was even found to be higher 
than the one presented by BMCS [50, 53]. Furthermore, in 
one-way mixed lymphocyte reactions, WJ-MSCs did not 
stimulate the proliferation of allogenic T cells, and in two-
way mixed lymphocyte reactions WJ-MSCs decreased the 
level of alloreactivity [50]. Importantly, it was also reported 
that WJ-MSCs express the mRNA for the immunosuppres-
sive HLA-G; lack the expression of CD40, CD80 and CD86, 
co-stimulatory receptors essential for immune response; and 
express mRNA for several cytokines, with IL-6 and VEGF 
being the most emphasized given their previously shown 
immunosupressive role [50]. Several other mRNAs for cyto-
kines and proliferation, growth, and anti-apoptotic factors, 
namely IL-1, IL-8, IL-11, IL-14, BMP1, CSF3, FAM3C, 
GDF15, PDGFB, TNF-4, -11b and -12, were detected as 
well [50]. Further studies also reported that WJ-MSCs in 
basal culture conditions express mRNAs for HGF, TGF-, 
COX-1 and COX-2 [52]. In accordance to the results of in 
vitro surveys, in vivo studies showed the low immunogenic 
profile of WJ-MSCs. When transplanted into rat brains, hu-
man WJ-MSCs were able to survive for 1 week with no 
signs of immune reaction against them [19]. Similar results 
were found after pig WJ-MSCs were transplanted into rat 
brains [62, 63], thus confirming that these cells can be seen 
as valid tools for future therapeutic applications. 
 The immunologic properties of HUCPVCs were also 
recently studied. Briefly, HUCPVCs were found to promote 
no proliferation when cultured with either resting or acti-
vated allogenic lymphocytes [64]. Additionally, both in one-
way and two-way mixed lymphocytes reactions, HUCPVCs 
were shown not only to reduce alloreactivity but also to at-
tenuate lymphocyte's activity, as seen through the reduction 
of CD25 expression [64]. Remarkably, the immunosuppres-
sive activity of HUCPVCs was found to be exerted, at least 
in part, through soluble factors, given that reduced levels of 
lymphocyte proliferation in mixed lymphocyte reactions 
were also seen when HUCPVCs and allogenic lymphocytes 
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were cultured in transwell systems [64]. More recently, our 
group also showed that conditioned media of these cells 
were able to reduce the densities of microglial cells, which 
are important mediators of the immune reaction within the 
CNS [65].  
2.3. Secretome 
 Proteomic/secretome studies performed on WJ-MSCs are 
still sparse, although they are of extreme importance for the 
identification of trophic factors relevant for biomedical ap-
plication, or cytokines taking part in the immunomodulatory 
interaction between WJ-MSCs and the immune system. In 
this respect, Yoo et al., already showed that WJ-MSC-
derived culture supernatants present several cytokines and 
other secreted factors, namely IL-2, IL-6, IL-8, IL-12, IL-15, 
MCP-1, MIP-1, RANTES and PDGF-AA [52]. The pres-
ence of chemoattractants such as MCP-1, MIP-1, RANTES 
and PDGF-AA suggests that WJ-MSCs, and more impor-
tantly their secretory activity, can beneficially interact with 
the immune system by boosting the prompt mobilization of 
immune cells. The presence of pro-inflammatory cytokines 
in the conditioned medium of WJ-MSCs [52], as well as the 
expression of pro-inflammatory cytokine mRNAs [50] are in 
conflict with the immunosuppressive activity of these cells. 
Given that expression of mRNA for the immunosuppressive 
cytokine IL-10 was not found, and no IL-10 was detected in 
WJ-MSCs conditioned medium, a possible explanation for 
such results might again be the secretion of TGF-, whose 
mRNA expression was detected [52]. Besides that, it is rea-
sonable to think that WJ-MSCs might suffer a change in 
their secretory profile when exposed to an immunoreactive 
environment, much like what was already reported for ASCs 
[66]. Also noteworthy is the fact that no VEGF was found in 
the secretome of WJ-MSCs [52], suggesting that although 
VEGF mRNA was detected by Weiss et al., the protein may 
not be secreted, or even synthesized. Interestingly, some 
reports in which WJ-MSCs were transplanted into animal 
models of brain stroke [67] or myocardial infarction [68] 
have suggested that indeed WJ-MSCs are able to secrete 
VEGF in vivo. Taking into account that no VEGF was found 
in in vitro studies, such results may indicate that on the con-
text of a lesion, where cells are exposed to an inflammatory 
environment, WJ-MSCs can suffer a change in their secre-
tory profile. Other secretome studies were able to prove the 
presence of HGF in WJ-MSCS culture medium, as well as 
appreciable levels of prostaglandin E-2 (PGE2) [53]. Interest-
ingly, in the same report it was shown that stimulation of 
WJ-MSCs with either IFN- or TNF-, major players in 
immune responses, does not compromise their low immuno-
genic profile, nor their ability to attenuate alloreactivity in in 
vitro mixed lymphocytes reactions [53]. Remarkably, the 
ability of WJ-MSCs to reduce alloreactivity was even in-
creased upon IFN- stimulation [53]. These results, although 
performed in vitro, suggest that the immunomodula-
tory/immunosuppressive activity of WJ-MSCs might not be 
affected when transplanted into organs or tissues where ac-
tive immune response is underway. Moreover, since expo-
sure to pro-inflammatory stimuli was able to boost the im-
munosuppressive character of WJ-MSCs, this report further 
supports the hypothesis that the immunomodulatory activity 
of WJ-MSCs, and thus the secretome profile underpinning 
such phenotype, might change when cells are exposed to an 
immunologically active environment. Still, in vivo data need 
to be further provided in order to have a clearer picture on 
this. 
 The trophic action of MSCs isolated from the WJ in the 
perivascular regions has also been shown. For instance, our 
group has recently revealed how HUCPVCs secretome 
modulates the action of CNS cells [65]. Moreover, we have 
recently observed that HUCPCVs also secrete HGF, VEGF, 
NGF, SCF and FGF (unpublished data). In another study the 
comparative proteomic analysis of HUCPVCs, placenta-
derived MSCs and BMSCs, revealed that HUCPVCs express 
higher levels of manganese superoxide dismutase (MnSOD) 
and plasminogen activator inhibitor-1 (PAI-1) [69]. These 
results suggest that HUCPVCs may have reduced migration 
ability, given that both these proteins are known to be in-
volved in the migration of cells [69]. Such hypothesis was 
confirmed through a trans-matrigel migration assay, in which 
HUCPVCs presented the lowest migration ability [69]. Fur-
thermore, they also presented higher levels of GRP-75, a 
protein widely implicated in cell proliferation [69], and that 
can help explaining the higher proliferation rate of 
HUCPVCs when compared with other MSCs, namely WJ-
MSCs. 
 Regarding MSCs isolated from the endothe-
lial/subendothelial portion of the umbilical cord blood ves-
sels, a gene expression study revealed that these cells present 
several overexpressed genes when compared to umbilical 
cord blood MSCs. Among those overexpressed genes are 
synpo2 (synaptoidin) and nrp2, involved in neurogenesis, 
and flt1 (vascular endothelial growth factor – VEGF), which 
is implicated in angiogenesis [61]. In yet another gene ex-
pression comparative analysis was described the high ex-
pression of several genes coding for proteins implicated in 
angiogenesis, namely CXCL6 and IL-8, in endothe-
lial/subendothelial MSCs, when compared to BMSCs [59]. 
More recently, Koh et al., [60] performed a quite objective 
analysis of their secretome, targeting growth factors with 
known neuroprotective role. They were able to identify the 
presence of relevant amounts of G-CSF, VEGF, GDNF and 
BDNF. The secretory activity of endothelial/subendothelial 
MSCs was even higher than that of BMSCs. 
2.4. MSCs from the Umbilical Cord and CNS Regenera-
tive Medicine 
 Much like BMSCs and ASC, WJ-MSCs also present sev-
eral characteristics that make them suitable alternatives for 
cell-based therapeutical use. To assess this hypothesis, spe-
cifically in the context of CNS lesions, several studies em-
ployed WJ-MSCs as experimental treatments. For instance, 
WJ-MSCs were already experimentally used for the treat-
ment of spinal cord lesions in animal models. After complete 
transection of the rat spinal cord the transplantation of hu-
man WJ-MSCs into the lesion site and both rostral and cau-
dal stumps was able to promote axonal re-growth across the 
injured area [70]. Remarkably, transplanted animals also 
presented increased density of neurofilament-positive fibers 
in the transected area, which was concomitant with signifi-
cant functional improvements [70]. As discussed elsewhere, 
one of the major hurdles for the regeneration of spinal cord 
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injury sites, is the formation of a glial scar [71, 72]. In this 
respect, WJ-MSC-treated animals showed, when compared 
to untreated controls, a clear reduction in microglial activa-
tion and glial scar formation [70]. Interestingly, three weeks 
after lesion several cytokines and growth factors were found 
to be overexpressed in transplanted animals, namely neu-
rotrophin-3 (NT-3) and bFGF, which are known to exert a 
protective and regenerative action in spinal cord lesions [70, 
73, 74].  
 The beneficial action of WJ-MSCs was also reported in 
experimental models of cerebral ischemia. Rat WJ-MSCs 
were shown to have a protective action when transplanted 
three days before a cardiac arrest-induced global ischemia 
[75]. When unilaterally injected into the dorsal thalamic nu-
cleus, dorsal hippocampus, corpus callosum and dorsal cor-
tex, these cells significantly reduced the extent of neuronal 
damage in the hippocampus [75]. Remarkably, such effects 
were seen in both ipsilateral and contralateral hemispheres 
[75]. To further understand the impact of the treatment with 
rat WJ-MSCs, another study used the same experimental 
design and assessed the levels of astrocytic and microglial 
activation [76]. As hypothesized by the authors, the reduc-
tion in Vimentin (VIM)- and Nestin (NES)-positive cells in 
treated animals suggests a decrease in inflammatory reaction 
after global ischemia. These markers are usually overex-
pressed during astrocytosis; however, they are also present in 
neuronal precursors. Although no double stainings for 
VIM/NES and specific astrocyte markers were performed, 
significant positive correlations between VIM/NES staining 
and neuronal damaged were reported [76]. Additionally, 
regarding microglia response to global ischemia, the authors 
describe a decrease in activation, positively correlated with 
reduced neuronal damage [76]. Besides rat WJ-MSCs, sev-
eral lines of evidence have reported that human WJ-MSCs 
may also be beneficial for the treatment of brain ischemia. 
Ding et al., described that in stroke-subjected rats the trans-
plantation of human WJ-MSCs is able to promote functional 
recovery of behavioral deficits, as seen through locomotor 
activity evaluations and neurochemical imaging techniques 
[49]. Furthermore, transplanted animals presented reduced 
lesion size and a higher extent of vascularization in ischemic 
areas [49]. An also important result came from the co-
transplantation of WJ-MSCs with a 1-integrin antagonist. 
As reported, 1-integrin levels were increased in WJ-MSCs 
treated animals; however, the addition of such antagonist 
blocked both the functional recovery and the angiogenic 
process, showing the direct implication of 1-integrin in the 
recovery of ischemic tissues [49]. Still in the same study, 
higher expression of SDF-1, BDNF and GDNF was found in 
ischemic tissues following WJ-MSCs treatment, which sug-
gests that these cells have the ability to induce an upregula-
tion in molecular pathways implicated in neuroprotection 
and angiogenesis.  
 Similar results were also described in studies using hu-
man MSCs isolated from the endothelial/subendothelial por-
tion of umbilical cord blood vessels [60] or a mixed popula-
tion of umbilical cord-derived MSCs, certainly comprising 
WJ-MSCs, HUCPVCs and endothelial/subendothelial MSCs 
[67]. In the later, besides a significant functional recovery 
and reduction of the ischemic area, the authors also reported 
increased levels of VEGF and bFGF near lesioned areas 
[67]. Importantly, immunohistochemical analysis strongly 
suggested the involvement of transplanted cells in the secre-
tion of the factors [67].  
 Common to some studies was the presence of labeled 
WJ-MSCs expressing neuronal and glial markers, suggesting 
the in vivo differentiation of these cells towards those linea-
ges [49, 60, 67]. The possibility of cell fusion cannot be ex-
cluded, but even if differentiation occurs, the incidence of 
such events so far reported is certainly too low to account for 
the positive action of the transplantation protocols. Instead, 
given the growing body of evidence proving that umbilical 
cord-derived MSCs secretome is rich in growth factors, the 
trophic activity of these cells seems to be much more rele-
vant for their in vivo impact. 
 Apart from spinal cord lesions and brain ischemia, the 
therapeutical potential of umbilical cord-derived MSCs for 
the treatment of Parkinson’s disease was already assessed. In 
a 6-OHDA-injected hemiparkinsonian rat model, the trans-
plantation of human WJ-MSC into the striatum was able to 
promote functional recovery at the level of the dopaminergic 
system, as seen by the reduction in apomorphine-induced 
turning behavior [19]. Moreover, the authors also described 
improvements at the histological level, where increased 
staining for tyrosine hydroxylase was found in WJ-MSC-
transplanted animals. Noteworthy is the fact that the authors 
reported an absence of WJ-MSCs three months pos-
transplantation on the injected sites, and the inexistence of 
neurons/glial cells differentiated from them.  
 Finally, data regarding the possible applications of 
HUCPVCs in the CNS is scarcer than that concerning WJ-
MSCs use. Nevertheless, our group has recently shown that 
HUCPVCs conditioned media, and thus their secretome, 
increase glial cell viability and proliferation [65]. Further-
more, it was also observed that glial cell cultures exhibited 
higher numbers of GFAP positive cells (astrocytes) and O4 
positive cells (oligodendrocytes) when incubated with the 
CM. Additionally, it was also observed that the growth fac-
tors present in the CM did not induce an increase on the mi-
croglial cells number, as mentioned earlier. For hippocampal 
neurons similar results were obtained, as cultures exposed to 
HUCPVCs CM disclosed higher numbers of MAP-2 positive 
cells. Moreover, it was also observed that the cell viability 
and proliferation in this primary hippocampal cell culture 
system were also higher, when compared to control cultures. 
Therefore, these experiences allowed us to conclude that the 
secretome of these cells may have a modulatory effect on 
CNS cells [65]. Moreover, current experiments performed in 
our lab have shown that the CM of HUCPVCs is able to in-
duce an increase of GFAP, MAP-2 and nestin positive cells 
(without co-localization with HUCPVCs) when injected in 
the rat hippocampus (unpublished data). Finally we were 
also able to observe a similar trend to that reported by Weiss 
et al. [19] when HUCPVCs were transplanted into a unilat-
eral 6-OHDA-lesioned PD rat model (unpublished data). 
CONCLUDING REMARKS 
 There are now several studies strongly suggesting that 
MSCs isolated from different areas of the umbilical cord, 
other than the blood, present low immunogenic potential and 
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an ability to modulate the activity of immune cells to the 
extent of decreasing immune reaction towards allogenic 
cells. Additionally, there is also robust evidence on the bene-
ficial actions of these cells in different in vitro and in vivo 
CNS models of survival, proliferation, differentiation and 
injury. On the light of these discoveries, these MSC popula-
tions might be good candidates for future clinical applica-
tions within CNS regenerative medicine. The expression of 
several growth factors also raises the possibility that these 
cells can be further used to exert protection/differentiaton 
under the same context. However, and contrary to what hap-
pens with BMSCs and ASCs, the proteome and secretome of 
these umbilical cord derived MSCs are still poorly studied 
and more experiments need to be conducted in order to fur-
ther characterise their properties. Moreover, it would be also 
interesting to study how these cells integrate within the 
neuro-oncology field. For instance, a number of recent pa-
pers have revealed the tropism of MSCs towards malignant 
tumours, making these cells a potential vehicle for delivery 
of therapeutic genes to disseminated glioma cells. Finally in 
vivo studies should be designed in order to adequately assess 
if the histological improvements frequently observed, are 
matched by relevant functional outcomes. By doing so it will 
be possible to better understand the true potential for these 
cells to be used in CNS regenerative medicine. 
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